All sponsors

Edgewise Therapeutics, Inc. $EWTX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING1
READOUTS ≤12 MONTHS2
Open Edgewise Therapeutics, Inc. on the live radar map → 📅 $EWTX readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Sevasemten Dose 1
NCT05540860
P2Active, not recruitingDuchenne Muscular Dystrophy762027-01 (+31 mo)
FOX
NCT06100887
P2Active, not recruitingDuchenne Muscular Dystrophy432027-03 (+21 mo)
EQUINOX
NCT07795814
P2RecruitingHeart Failure With Preserved Ejection Fraction902027-12
EDG-7500
NCT06347159
P2Active, not recruitingHypertrophic Cardiomyopathy792027-12 (+33 mo)
MESA
NCT06066580
P2Enrolling by invitationBecker Muscular Dystrophy2602031-02 (+35 mo)